title: [Migraine with pleocytosis: a case of atypical progression].
abstract: OBJECTIVE
  Migraine with cerebrospinal fluid pleocytosis is a clinical pattern consisting in intermittent headaches accompanied by episodes of transient neurological deficit and lymphocytic pleocytosis, which last for varying lengths of time and have a spontaneous resolution. We describe the case of migraine with pleocytosis (MP) with atypical progression that responded well to corticoids.
  
  
  METHODS
  A 27 year old male with no familial or personal history of migraine who began with bouts of intense headaches that were preceded by neurological deficit (dysphasia and hemiparesis of the right hand side) lasting varying amounts of time (including hours). The serial study of cerebrospinal fluid (CSF) revealed a notable degree of lymphocytosis (400/mm3) with increased intracranial pressure (ICP) (> 30 mmHg). The other explorations that were performed (microbiological study of CSF and blood, humoral and cellular immunity, MR angiography and thyroid hormones, among others) were all normal. The neurological exploration carried out in the following days revealed a mild paresis of the right lateral rectus muscle, which was attributed to the intracranial hypertension and which clearly disabled the patient. As a consequence of the recurrence of the seizures and the long lasting increase in ICP, therapy was begun with 1 mg/kg/day of prednisone, at a descending rate; clinical remission and normalisation of the CSF was achieved within a period of two months.
  
  
  CONCLUSIONS
  We describe this case of MP because of how atypical the progression was (paresis of the right abducent nerve secondary to the increase in ICP) and the possibility of associating corticoids in cases in which the benignity of the entity is in doubt.
authors.affiliation: Hospital Clinico Universitario Lozano Blesa, Zaragoza, España. ssantosl@yahoo.com
authors.forename: S
authors.initials: S
authors.lastname: Santos
authors.forename: B
authors.initials: B
authors.lastname: Sierra Bergua
authors.forename: I
authors.initials: I
authors.lastname: de los Mártires Armingol
authors.forename: J
authors.initials: J
authors.lastname: Navarro Calzada
authors.forename: C
authors.initials: C
authors.lastname: Pérez Lázaro
authors.forename: M
authors.initials: M
authors.lastname: Garcés Redondo
authors.forename: O
authors.initials: O
authors.lastname: Fabre Pi
authors.forename: C
authors.initials: C
authors.lastname: Tejero Juste
authors.forename: P
authors.initials: P
authors.lastname: Larrodé Pellicer
authors.forename: L J
authors.initials: LJ
authors.lastname: López del Val
authors.forename: L F
authors.initials: LF
authors.lastname: Pascual Millán
mesh_terms: D020434:Abducens Nerve Diseases / Q000209:etiology; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001037:Aphasia / Q000209:etiology; D002555:Cerebrospinal Fluid / Q000166:cytology; D018450:Disease Progression; D006801:Humans; D019586:Intracranial Hypertension / Q000209:etiology; D007964:Leukocytosis / Q000209:etiology*; D008297:Male; D008881:Migraine Disorders / Q000134:cerebrospinal fluid* / Q000150:complications / Q000188:drug therapy; D010291:Paresis / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use; D012008:Recurrence
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone